Cardiac Trials Acute Coronary Syndrome Trials IMPROVE-IT Purpose: to establish the benefit and safety of Vytorin versus simvastatin monotherapy in high risk patients hospitalized with acute coronary syndrome. (Note: closed to enrollment) Principal Investigator - Dr. H. T. Dale Sub Investigators TRA- 2p TIMI 50 Purpose: to evaluate the safety and efficacy of the study medication in addition to standard of care in subjects with a history of atherosclerotic disease. (Note: closed to enrollment) Principal Investigator - Dr. P. Puleo Sub Investigators TABY Purpose: to compare Prasugrel versus Clopidogrel (Plavix) in patients hospitalized for acute coronary syndrome (ACS) who are medically managed. Principal Investigator - Dr. L. Tejada
Sub Investigator - Dr. J. Gallagher TIMI- 52 Purpose: to evaluate the safety and efficacy of the study medication versus placebo in addition to the standard of care in subjects hospitalized with an acute coronary syndrome (ACS). The study medication decreases the inflammatory response which contributes to atherosclerotic disease. Principal Investigator - Dr. P. Puleo Sub Investigators
Pulmonary Trials LOTT Purpose: This study is investigating the effects of oxygen therapy in two types of patients with Chronic Obstructive Pulmonary Disease (COPD). We already know that 24-hour oxygen therapy improves and prolongs the lives of people with COPD who have a very low level of oxygen in their blood at rest, but we do not know if oxygen therapy helps two other types of people with COPD: COPD patients who have a moderately low level of oxygen in their blood at rest and COPD patients who have normal blood oxygen level at rest but low or very low blood oxygen during exercise Principal Investigator - Dr. M. Turki
Sub Investigator - Dr. C. Alia STATCOPE Purpose: a clinical trial designed to determine the effect of 40 mg of daily Simvastatin versus placebo on decreasing the frequency and severity of COPD exacerbations Principal Investigator - Dr. M. Turki
Sub Investigator - Dr. C. Alia
Diabetic Studies ELIXA Purpose: to evaluate the cardiovascular outcomes with a subcutaneous injection of the study drug lixisenatide compared to placebo, in addition to standard of care, in type 2 diabetic patients who experienced an acute coronary syndrome event. Principal Investigator - Dr. H. T. Dale
Sub Investigator - Dr. B. A. Bhatt EXAMINE Purpose: to evaluate the cardiovascular outcomes following treatment with Alogliptin versus placebo, in addition to standard of care, in patients with type 2 diabetes and acute coronary syndrome Principal Investigator - Dr. H. T. Dale
Sub Investigator - Dr. B. A. Bhatt TIMI 53 Purpose: a phase IV study to evaluate if treatment with Onglyza (saxagliptin) versus placebo, in addition to standard of care, can reduce major adverse cardiovascular events in patients with type 2 diabetes Principal Investigator - Dr. L. Tejada Sub Investigators
Heart Failure CARRESS Purpose: to evaluate the safety and effectiveness of Aquapheresis/ Ultrafiltration or diuretic therapy for the treatment of patients with persistent congestion (fluid buildup) and cardiorenal syndrome (kidney function which is not normal). Aquapheresis/Ultrafiltration is not an experimental procedure. Principal Investigator - Dr. A. Potash Sub Investigators
Registries TRANSLATE-ACS Purpose: an observational study of patients with acute myocardial infarction (heart attack), managed with percutaneous coronary intervention (PCI) and antiplatelet therapy. The study will examine long-term effectiveness and safety of antiplatelet therapies, post-discharge care patterns and treatment adherence, and associated health care costs. Principal Investigator - Dr. P. Puleo |